# ClinicalTrials.gov record NCT03973047

> PeptideScanner retained ClinicalTrials.gov record NCT03973047 at 2026-07-30T19:40:58.916Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was bremelanotide.

- Evidence object: `story:clinicaltrials-gov-nct03973047-bremelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03973047-bremelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03973047-bremelanotide-v1.json
- Content SHA-256: `02577f1466573817e881bbc9ee9ecc4765fb6214960f7569bcd663ae2269c336`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03973047 ([`ctg-observation-nct03973047-2022-04-04-497b0f4b3810`](#source-ctg-observation-nct03973047-2022-04-04-497b0f4b3810))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03973047 at 2026-07-30T19:40:58.916Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was bremelanotide. ([`ctg-observation-nct03973047-2022-04-04-497b0f4b3810`](#source-ctg-observation-nct03973047-2022-04-04-497b0f4b3810))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03973047 at 2026-07-30T19:40:58.916Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was bremelanotide. ([`ctg-observation-nct03973047-2022-04-04-497b0f4b3810`](#source-ctg-observation-nct03973047-2022-04-04-497b0f4b3810))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03973047-2022-04-04-497b0f4b3810`](#source-ctg-observation-nct03973047-2022-04-04-497b0f4b3810))

## Sources

<a id="source-ctg-observation-nct03973047-2022-04-04-497b0f4b3810"></a>
- **ClinicalTrials.gov record NCT03973047 · retained source version 2022-04-04:497b0f4b3810b80bcb52e7ad920e589233946a10ef53c3144ff39d185cd03b8a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03973047) (`ctg-observation-nct03973047-2022-04-04-497b0f4b3810`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03973047." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03973047-bremelanotide-v1.json SHA-256: 02577f1466573817e881bbc9ee9ecc4765fb6214960f7569bcd663ae2269c336.